SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 11, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced the appointment of Eliav Barr , M.D., to its board of directors, effective immediately. “We are thrilled to welcome Eliav Barr to our board,” said Marc Stapley , Veracyte’s chief executive
Grew Total Revenue to $72.9 million , an Increase of 32% Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 2, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the second quarter ended June 30, 2022 .
The Genomic Test Demonstrated 100 Percent Sensitivity and 100 Percent Specificity for MTC SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 20, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced that new clinical validation data published online in Thyroid show that the company’s RNA
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 14, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the second quarter of 2022 after the close of market on Tuesday, August 2, 2022 . Company management will host a conference call and webcast to
Findings from a large, multi-cohort study suggest the genomic test can improve care for lung nodule patients with inconclusive bronchoscopy results SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 13, 2022-- Veracyte, Inc . (Nasdaq: VCYT) announced that new data published today in PLOS ONE show
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 27, 2022-- Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company, today announced that it has been named a Bay Area Top Workplace for the ninth consecutive year. The annual award is based solely on employee feedback gathered through an
Meta-analysis of independent, real-world studies was presented at ENDO 2022 and shows even better Afirma GSC performance compared to original clinical validation study SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 20, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced that findings from a
First randomized, clinical study demonstrating prognostic value of Decipher Prostate test in postoperative salvage setting without hormone therapy SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 3, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced the publication of data reinforcing the
Findings from Phase II AtezoTRIBE trial published online in The Lancet Oncology SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 31, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that new data published online in The Lancet Oncology suggest that the company’s Immunoscore Immune Checkpoint
- First findings from study analyzing outcomes of more than 10,000 men in national SEER database who underwent Decipher testing - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 26, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced that new data from a large, population-based study
The information in our press releases and webcasts should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these press releases or presentations.
